ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0099

Interleukin 6 Concentration in Synovial Fluid of Patients with Different Types of Arthritis
Abstract Number: 0100

Concordance Between the QuantiFERON-TB Gold In-Tube and Tuberculin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Rheumatic Diseases
Abstract Number: 0101

Romosozumab After Denosumab Improves Lumbar Spine and Maintains Total Hip Bone Mineral Density in Postmenopausal Women with Low Bone Mass
Abstract Number: 0102

Bone Health in Patients with Psoriatic Arthritis in the National Swiss Cohort: A Cross-sectional Study
Abstract Number: 0103

The Association of Methotrexate, Sulfasalazine and Hydroxychloroquine Use with Incident Fractures in Postmenopausal Women with Rheumatoid Arthritis: Findings from the Women’s Health Initiative
Abstract Number: 0104

Bone Effects of One-year Tofacitinib Treatment in Rheumatoid Arthritis
Abstract Number: 0105

Use of Peripheral Quantitative Computed Tomography in the Assessment of Bone Mineral Density in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients
Abstract Number: 0106

A Machine Learning-derived Radiomics Nomogram for Diagnosis of Osteoporosis and Osteopenia
Abstract Number: 0107

Effects of Abaloparatide on Modeling and Remodeling Based Bone Formation
Abstract Number: 0108

The Relationship Between Body Fat Percentage and Bone Mineral Density in Rheumatoid Arthritis Patients
Abstract Number: 0109

Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?
Abstract Number: 0110

Does Urate Directly Influence Bone Turnover? Randomized Controlled Trial of Inosine Supplementation
Abstract Number: 0111

Assessment and Treatment of Glucocorticoid-Induced Osteoporosis in a Rheumatology Clinic
Abstract Number: 0112

Description of Risk Factors at Baseline and Need of Bone Agent According to Hadji Recommendations in Patients Taking Aromatase Inhibitors as Breast Cancer Therapy
Abstract Number: 0113

Improving Glucocorticoid-Induced Osteoporosis Screening and Management in Patients with Rheumatic Diseases Using the 2017 ACR Guidelines

« Previous Page
1
…
7
8
9
10
11
…
139
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].